Biotechnology Focus Podcast

And, that was Dr. Christopher Gemmiti, a regenerative medicine professional, making a pitch before a panel of judges, for his company RedactBio.

This was during the Perfect Pitch competition held at the recent Toronto conference The Business of Regenerative Medicine.

The conference was a three day event organized by the Commercialization Centre for Regenerative Medicine.

Even at the best of days, making a pitch before potential funders can be a daunting, if not un nerving task for any entrepreneur in any industry.

But, is there a secret formula for making the perfect pitch?

We talked to Michael May, chief executive officer of the CCRM.

I hope you enjoyed this edition of the Biotechnology Focus Podcast.

From September 11th to the 12th this year, Vantage Bio trials will be holding its 2nd annual Canada Talks Pharma conference. The event is an opportunity for professionals in the biotechnology and pharmaceutical industries to get together, exchange views, and learn about innovative ideas, new technologies, and clinical research methods.

Biotechnology Focus spoke with Vatche Bartekian, president and founder of Vantage Bio Trials.

Vatche told us what's in store for attendees in this year's Canada Talks Pharma.

Have a listen to what he had to say....

In this episode of the Biotechnology Podcast, we report of the successful results of Merck's anacetrapib trials. Dr. Don Stewart, principal of Canadian biotech firm PlantForm discusses why his company is building a laboratory in Brazil. We also take a look at Mississauga's new life science strategy.

By now, it's no longer a surprise for anyone that the medical marijuana market

in the country is geared for explosive growth.

Recently Canada's national drug development and commercialization centre has partnered with Vancouver's Aequus Pharmaceuticals Inc.,

on a research program aimed at establishing pre-clinical safety

and efficacy of select cannabinoid-based therapeutics.

I had a chance to speak with Gordon McCauley, president and CEO of the

 Centre For Drug Research and Development  or CDRD.

And he provided Biotechnology Focus with some insights into his organization's partnership with Aequus.

Have a listen to our conversation….

CRISPR genome editing could hold the key for treating and curing diseases such as cancer, leukemia, and HIV/AIDS.

But However, Dr. J. Keith Joung of Massachusetts General Hospital warns there is growing evidence that CRISPR could alter regions of the genome which researchers are not targeting. What are the consequences? The iconic Canadian rock band Tragically Hip is one of the latest investors in the country's growing medical marijuana market.

We've got these and more in this episode of the Biotechnology Podcast…

Click on these links to read full stories:

RESEARCHERS WARNED OF CRISPR OFF-TARGET EFFECTS

THREE U OF G GETS GENOMICS RESEARCH GET $10.7-M SUPPORT

TRAGICALLY HIP PARTNERS WITH ONTARIO CANNABIS PRODUCER

In this episode of the Biotechnology Focus Radio, Liam Kaufman, co-founder of Winterlight Labs discusses with us how AI is powering his company's speech-based diagnostic platform. This platform natural speech to detect and monitor dementia, aphasia, and various cognitive conditions.

About Winterlight Labs:

WinterLight Labs is developing a proprietary AI diagnostic platform that can objectively assess and monitor cognitive health. The company's platform can analyze natural speech to detect and monitor dementia, aphasia, and various cognitive conditions.

Using a short one-minute sample of speech, WinterLight can characterize the speaker's cognitive, acoustic and linguistic state, including lexical diversity, syntactic complexity, semantic content, and articulation.

Using samples of a person's speech, WinterLight's platform analyzes hundreds of linguistic cues and can detect dementia of the Alzheimer type and other conditions with accuracies between 82% and 100%, as reported in our peer-reviewed academic studies. 

To find out more, click on this link: http://www.winterlightlabs.com/index.html

At a recent Mississauga Board of Trade event, we caught up with Canada's Science Minister, the Hon. Kirsty Duncan.

Fresh from her trip to Washington, where she spoke with American scientists and

championed the need for greater cross-border collaborative research between Canadian and American scientist,

the minister took the time to learn about Mississauga's new Life Science's focused development strategy.

Ms. Duncan also discussed with Biotechnology Focus why she believes the sector should be in the forefront of Canada's innovation strategy, her ongoing review of Canada's science and innovation strategy, and the creation of new science research chair positions.

---

That was the Hon. Kirsty Duncan, science minister of Canada, discussing the important roles that the biotechnology and life sciences sectors play in the country's development, and

The review of canada's science strategy.

I hope you enjoyed this week's show.

This is you host, Nestor Arellano,

Inviting you to tune in again next week, on the Biotechnology Focus Radio.

Over 1 billion people around the world suffer from "needle phobia."

Each year, there are countless people who avoid critical therapies and vaccinations simply because of their fear of hypodermic needles.

Vancouver's Microdermics Inc.is determined to change all that with its work on an innovative drug delivery system which promises to be safer, less painful, and more cost-effective than traditional hypodermic needles.

In this episode of the Biotechnology Focus Podacst, Rory St. Claire, director of technical operations at Microdermics, talks about the unique features of his company's proposed alternative to a medical tool that has been known to make even grown men cry for more than 160 years.